Coeptis Therapeutics Inc.
COEP | NASDAQ
$10.99
$0.00 (0.00%)
Nov 2, 2026, 3:59 PM ET · Market open
Fiscal Year Period Ending | FY 2025 Dec 31, 2025 | FY 2024 Dec 31, 2024 | FY 2023 Dec 31, 2023 | FY 2022 Dec 31, 2022 | FY 2021 Dec 31, 2021 | FY 2020 Dec 31, 2020 |
|---|---|---|---|---|---|---|
Revenue | 1.36M | n/a | n/a | n/a | 75K | 30.76K |
Cost of Revenue | 180.63K | n/a | n/a | n/a | n/a | 964.22K |
Gross Profit | 1.18M | n/a | n/a | n/a | 75K | -933.46K |
Operating Income | -13.04M | -10.05M | -21.49M | -34.2M | -14.05M | -6.86M |
Interest Income | 116.5K | n/a | n/a | n/a | n/a | n/a |
Pretax Income | -12.28M | -10.88M | -21.27M | -37.57M | -13.45M | -9.16M |
Net Income | -11.92M | -10.68M | -21.27M | -37.57M | -13.45M | -9.16M |
Selling & General & Admin | 11.95M | 6.72M | 13.82M | 34.18M | 14.12M | 5.78M |
Research & Development | 1.28M | 2.33M | 6.67M | 20.89K | n/a | 3.54K |
Other Expenses | 1M | 1M | 1M | n/a | n/a | 148.19K |
Operating Expenses | 14.23M | 10.05M | 21.49M | 34.2M | 14.12M | 5.93M |
Interest Expense | 642.38K | 396.12K | 107.69K | 218.41K | 187.13K | 148.19K |
Selling & Marketing Expenses | 105K | n/a | 12.71K | 8.33K | 2.92K | 6.61K |
Cost & Expenses | 14.41M | 10.05M | 21.49M | 34.2M | 14.12M | 6.89M |
Income Tax Expense | n/a | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 4.23M | 1.93M | 25.69M | 14.3M | 1.02M | 20.44M |
Shares Outstanding (Diluted) | 4.23M | 1.93M | 25.69M | 14.3M | 1.02M | 20.44M |
EPS (Basic) | -2.81 | -5.65 | -0.83 | -2.87 | -13.16 | -0.45 |
EPS (Diluted) | -2.81 | -5.65 | -0.83 | -2.87 | -13.16 | -0.45 |
EBITDA | -10.41M | -9.38M | -20.12M | -36.35M | -12.81M | -8.68M |
EBIT | -11.63M | -10.42M | -21.16M | -37.36M | -13.26M | -9.01M |
Depreciation & Amortization | 1.22M | 1.04M | 1.04M | 1M | 447.41K | 323.43K |
Add to Watchlist
Select watchlists to add or remove COEP